Role of growth factors, steroid and peptide hormones in the regulation of human prostatic tumor growth

Journal of Steroid Biochemistry and Molecular Biology

Volumn 56, Issue 1-6, 1996, Pages 107-111

  Motta, Marcella ^a   Dondi, D ^a   Moretti, R M ^a   Marelli, M Montagnani ^a   Pimpinelli, F ^a   Maggi, R ^a   Limonta, P ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GONADORELIN AGONIST; PEPTIDASE; TESTOSTERONE; TRANSFORMING GROWTH FACTOR ALPHA;

CELL LINE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; MALE; PROSTATE CANCER; TUMOR CELL; TUMOR GROWTH;

EID: 0029883937     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-0760(95)00240-5     Document Type: Conference Paper

References (36)

1. Horoszewicz J. S., Leong S. S., Kawinski E., Karr J. P., Rosenthal H., Ming Chu T., Mirand E. A. and Murphy G. P.: LNCaP model of human prostatic carcinoma. Cancer Res. 43 (1983) 1809-1818.
2. Veldscholte J., Ris-Stalper C., Kuiper G. G. J. M., Jenster G., Berrevoets C., Claassen E., van Rooij H. C. J., Trapman J. and Brinkmann A. O.: A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun. 17 (1990) 534-540.
3. Stone K. R., Mickey D. D., Wunderli H., Mickey G. H. and Paulson D. F.: Isolation of a human prostate carcinoma cell line (DU 145). Int. J. Cancer 21 (1978) 274-281.
4. Culig Z., Klocker H., Eberle J., Kaspar F., Hobisch A., Cranauer M. V. and Bartsch G.: DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reaction. Prostate 22 (1993) 11-22.
5. Sex hormones and antihormones in endocrine dependent pathology: basic and clinical aspects (Edited by M. Motta and M. Serio). Elsevier, Amsterdam (1994).
6. Limonta P., Dondi D., Moretti R. M., Maggi R. and Motta M.: Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LN-CaP. J. Clin. Endocr. Metab. 75 (1992) 207-212.
7. Limonta P., Dondi D., Moretti R. M., Fermo D., Garattini E. and Motta M.: Expression of luteinizing hormone-releasing hormone mRNA in the human prostatic cancer cell line LNCaP. J. Clin. Endocr. Metab. 76 (1993) 797-800.
8. Qayum A., Gullick W. J., Mellon K., Krausz T., Neal D., Sikora K. and Waxman J.: The partial purification and characterization of GnRH-like activity from prostatic biopsy specimens and prostatic cancer cell lines. J. Steroid Biochem. Molec. Biol. 37 (1990) 899-902.
9. Dondi D., Limonta P., Moretti R. M., Montagnani Marelli M., Garattini E. and Motta M.: Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop. Cancer Res. 54 (1994) 4091-4095.
10. Connolly J. M. and Rose D. P.: Autocrine regulation of DU 145 human prostate cancer cell growth by epidermal growth factor-related polypeptides. Prostate 19 (1991) 173-180.
11. Hofer D. R., Sherwood E. R., Bromberg W. D., Mendelsohn J., Lee C. and Kozlowski J. M.: Autonomous growth of androgen-independent human prostatic carcinoma cells: role of transforming growth factor α. Cancer Res. 51 (1991) 2780-2785.
12. Knabbe C., Kellner U., Schmahl M. and Voigt K.-D.: Growth factors in human prostate cancer cells: implications for an improved treatment of prostate cancer. J. Steroid Biochem. Molec. Biol. 40 (1991) 185-192.
13. Zuck B., Goepfert C., Nedlin-Chittka A., Sohrt K., Voigt K.-D. and Knabbe C.: Regulation of fibroblast growth factor-like protein(s) in the androgen-responsive human prostate cancer cell line LNCaP. J. Steroid Biochem. Molec. Biol. 41 (1992) 659-663.
14. Wilding G., Valverius E., Knabbe C. and Gelmann E. P.: Role of transforming growth factor-α in human prostate cancer cell growth. Prostate 15 (1989) 1-12.
15. Connolly J. M. and Rose D. P.: Production of epidermal growth factor and transforming growth factor-α by the androgen-responsive LNCaP human cancer cell line. Prostate 16 (1990) 209-218.
16. MacGrogan D., Saint-Andre J. P. and Dicou E.: Expression of nerve growth factor and nerve growth factor receptor genes in human tissues and in prostatic adenocarcinoma cell lines. J. Neurochem. 59 (1992) 1381-1391.
17. Schuurmans A. L. G., Bolt J., Veldscholte J. and Mulder E.: Regulation of growth of LNCaP human prostate tumor cells by growth factors and steroid hormones. J. Steroid Biochem. Molec. Biol. 40 (1991) 193-197.
18. Eaton C. L., Davies P., Harper M., France T., Rushmere N. and Griffiths K.: Steroids and the prostate. J. Steroid Biochem. Molec. Biol. 40 (1991) 175-183.
19. MacDonald A. and Habib F. K.: Divergent responses to epidermal growth factor in hormone sensitive and insensitive human prostate cancer cell lines. Br. J. Cancer 65 (1992) 177-182.
20. Limonta P., Moretti R. M., Dondi D., Montagnani Marelli M. and Motta M.: The EGF/TGFα system as an autocrine growth stimulatory loop in LNCaP cells. Endocr. Rel. Cancer 5 (1994) 5-13.
21. MacDonald A. T., Chisholm G. D. and Habib F. K.: Production and response of a human prostatic cancer cell line to transforming growth factor-like molecules. Br. J. Cancer 62 (1990) 579-584.
22. Tillotson J. K. and Rose D. P.: Endogenous secretion of epidermal growth factor peptides stimulates growth of DU 145 prostate cancer cells. Cancer Lett. 60 (1991) 109-112.
23. Henttu P., Liao S. and Vihko P.: Androgens up-regulate the human prostate-specific antigen messenger ribonucleic acid (mRNA), but down-regulate the prostatic acid phosphatase mRNA in the LNCaP cell line. Endocrinology 130 (1992) 766-772.
24. Kirschenbaum A., Ren M. and Levine A. C.: Enhanced androgen sensitivity in serum-free medium of a subline of LNCaP human prostate cancer cell line. Steroids 58 (1993) 439-444.
25. Negri-Cesi P., Motta M. with the technical assistance of Mornati O.: Androgen metabolism in the human prostatic cancer cell line LNCaP. J. Steroid Biochem. Molec. Biol. 51 (1994) 89-96.
26. Habib F. K., Busuttil A., Robinson R. A. and Chisholm G. D.: 5α-reductase activity in human prostate cancer is related to the histological differentiation of the tumor. Clin. Endocrinol. 23 (1985) 431-438.
27. Klein H., Bressel M., Kastendieck H. and Voigt K. D.: Quantitative assessment of endogenous testicular and adrenal steroids and of steroid metabolizing enzymes in untreated human prostatic cancerous tissue. J. Steroid Biochem. Molec. Biol. 30 (1988) 119-130.
28. Hudson R. W. and Wherrett D.: Comparison of the nuclear 5α-reduction of testosterone and androstenedione in human prostatic carcinoma and benign prostatic hyperplasia. J. Steroid Biochem. 35 (1990) 231-236.
29. Gittes R. E.: Carcinoma of the prostate. New Engl. J. Med. 324 (1992) 236-245.
30. Wilding G.: The importance of steroid hormones in prostate cancer. Cancer Surv. 14 (1992) 113-130
31. Kochman K., Kerdelhue B., Zor U. and Jutisz M.: Studies of enzymatic degradation of luteinizing hormone-releasing hormone by different tissues. FEBS Lett. 50 (1975) 190-194.
32. Lasdun A., Reznik S., Molineaux C. J. and Orlowski M.: Inhibition of endopeptidase 24.15 slows the in vivo degradation of LHRH. J. Pharm. Exper. Therap. 251 (1989) 439-447.
33. Molineaux C. J., Lasdun A., Michaud C. and Orlowski M.: Endopeptidase-24.15 is the primary enzyme that degrades LHRH both in vitro and in vivo. J. Neurochem. 51 (1988) 624-633.
34. Berger H., Schafer H., Klauschenz E., Albrecht E. and Mehlis B.: Rapid assay for in vitro degradation of luteinizing hormone releasing hormone. Anal. Biochem. 127 (1982) 418-425.
35. Berger H., Pliet R., Mann L. and Mehlis B.: Proteolytic inactivation of Luteinizing Hormone-Releasing Hormone (LHRH) by the whole rat ovary in vitro. Peptides 9 (1988) 7-12.
36. Carone F. A., Stetler-Stevenson M. A., May V., LaBarbera A. and Flouret G.: Differences between in vitro and in vivo degradation of LHRH by rat brain and other organs. Am. J. Physiol. 253 (1987) E317-E321.